Gastroenterology Research and Practice / 2019 / Article / Tab 1

Research Article

Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study

Table 1

Baseline characteristics of study patients.

CharacteristicsACEi/ARB ()CCB ()
(%) (%) value

Age, y, median (IQR)67.75 (58.41–75.52)67.97 (58.58–75.30)0.914
Gender>0.999
Female873 (39.9)873 (39.9)
Male1315 (60.1)1315 (60.1)
Cause of cirrhosis
Hepatitis B virus infection274 (12.5)274 (12.5)>0.999
Hepatitis C virus infection312 (14.3)283 (12.9)0.217
Alcoholic liver disease145 (6.6)147 (6.7)0.952
Other chronic hepatitis942 (43.1)922 (42.1)0.561
Comorbidity
Hypertension1982 (90.6)2000 (91.4)0.369
Diabetes mellitus845 (38.6)856 (39.1)0.756
Congestive heart failure222 (10.2)210 (9.6)0.577
Hyperlipidemia504 (23.0)501 (22.9)0.943
Drug exposure
Beta-blockers528 (24.1)542 (24.8)0.648
Statin159 (7.3)193 (8.8)0.067
Metformin542 (24.8)561 (25.7)0.531
Aspirin464 (21.2)478 (21.9)0.633
NSAIDs or COX-2862 (39.4)879 (40.2)0.621
ESRD29 (1.3)28 (1.3)>0.999
Competing mortality739 (33.8)928 (42.4)<0.001
Follow-up year (IQR)2.95 (1.26–5.78)3.14 (1.24–6.19)0.089

ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; COX-2: cyclooxygenase-2 inhibitors; ESRD: end-stage renal disease; IQR: interquartile range; NSAIDs: nonsteroidal anti-inflammatory drugs.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.